LM 2616

Drug Profile

LM 2616

Latest Information Update: 17 Nov 2003

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antiarrhythmics; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Heart failure

Most Recent Events

  • 17 Nov 2003 Discontinued - Preclinical for Heart failure in India (unspecified route)
  • 17 Nov 2003 Discontinued - Preclinical for Arrhythmias in India (unspecified route)
  • 26 Sep 1997 Preclinical development for Heart failure in India (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top